Immunoexpression of ALDH1A1, FGFR2, CD44 and Caspase-3 in Oral Squamous Cell Carcinoma and Leukoplakia: A pilot study

Current research highlighted the importance to recognize feasible biomarkers for early diagnoses and treatment in oral cancer. Our study analyzed the expression and spatial distribution of ALDH1A1, FGFR2, caspase-3, and CD44 in Oral Squamous Cell Carcinoma (OSCC) and leukoplakia with and without oral mucosal dysplasia. Paraffin-embedded samples of OSCC (n=5), leukoplakia with (n=5) and without (n=5) dysplasia obtained by incisional biopsies were processed using conventional histochemical techniques. Immunohistochemistry was performed using antibodies against ALDH1A1, FGFR2, caspase-3, and CD44. Images of the immunohistochemically stained tissue sections were analyzed according to the intensity of the immunostaining of each marker and classified in Scores. The Kruskal- Wallis test was performed (p≤0.05). Our results demonstrated a statically difference in the expression of all immunomarkers between OSCC and leukoplakia without dysplasia, being more significant in FGFR2 and ALDH1A1. Within the limitations of this study, our data showed that all biomarkers were overexpressed in OSCC and leukoplakia with oral mucosa dysplasia, suggesting that the presence of dysplasia is a significant clinic-pathologic predictor for malignant transformation.

La actual evidencia científica enfatiza la importancia de reconocer biomarcadores viables para el diagnóstico y tratamiento temprano del cáncer oral. Nuestro estudio piloto analizó la expresión y distribución espacial de ALDH1A1, FGFR2, caspasa-3 y CD44 en carcinoma oral de células escamosas (COCE) y en leucoplasia con o sin displasia de la mucosa oral. Las muestras incluidas en parafina de COCE (n=5), con (n=5) y sin (n=5) displasia fueron obtenidas mediante biopsias incisionales, las cuales se procesaron utilizando técnicas histoquímicas convencionales. El análisis inmunohistoquímico se realizó utilizando anticuerpos contra ALDH1A1, FGFR2, caspasa-3 y CD44. Las imágenes de las secciones de cada muestra fueron analizadas según la intensidad de inmunoexpresión de cada marcador y se clasificaron en diferentes escalas (scores). Se realizó la prueba de Kruskal-Wallis (valores de p<0,05). Nuestros resultados demostraron una diferencia estadística en la expresión de todos los inmunomarcadores entre COCE y las muestras con leucoplasia sin displasia, siendo más significativa en FGFR2 y ALDH1A1. Considerando las limitaciones de este estudio, los datos sugieren que la presencia de displasia en la mucosa oral es un importante predictor clínico-patológico de transformación maligna.

Possible role of ALDH1 and CD44 in lip carcinogenesis

Abstract Lip squamous cell carcinoma (LSCC) accounts for 12% of all head and neck cancers. It is caused by chronic exposure to ultraviolet light solar radiation and related to previous actinic cheilitis (AC). This study aimed to investigate the immunostaining of the putative cancer stem cells (CSC) markers ALDH1 and CD44 in AC (n=30) and LSCC (n=20). ALDH1 positivity was found to be statistically higher in LSCC than in AC lesions (p=0.0045), whilst CD44 expression was statistically higher in AC than in LSCC lesions (p=0.0155). ALDH1+ cells in AC lesions were associated with specific clinical features: a younger age (<60 years old), the female gender, white skin, not smoking or consuming alcohol, and a fast evolution, and not associated with the chronic exposure to UV radiation (p<0.0001). CD44 positivity was associated with patients who were male, feoderm, smoked, consumed alcohol, underwent occupational exposure to UV-radiation, and demonstrated lesions with log-time evolution (p<0.0001). ALDH1 + cells were associated with mild dysplasia using a system from the World Health Organization (WHO), and with a low risk of malignant transformation, according to the binary system (p<0.0001). CD44+ cells were also associated with moderated dysplasia, according to the WHO system. In LSCC, ALDH1 + cells were positively associated with patients who were older (≥ 60 years old), smokers, and with those who consumed alcohol (p<0.0001). CD44 + cells in LSCC were associated with older (≥ 60 years old) patients as well, but also with female patients, white skin, non-smokers, and individuals who did not consume alcohol (p<0.0001), all of whom showed distinct patterns in pre- and malignant lesions of both markers. Additionally, in LSCC, both ALDH1 and CD44 staining were associated with smaller tumor sizes (T1/T2; p<0.0001). In summary, although both ALDH1 and CD44 were associated with the presence of dysplasia in AC lesions, the present findings suggest that ALDH1 and CD44 may be activated by different etiopathogenic pathways, predominantly in distinct steps of oral carcinogenesis. CD44 would thus be more significantly related to the potentially malignant lesion, while ALDH1 would be closely linked to malignancy.

Estudo comparativo da expressão de ALDH1 em líquen plano oral, lesão liquenoide e leucoplasia em epitélio e no infiltrado inflamatório liquenoide / Comparative study of ALDH1 expression in oral lichen plane, lichenoid lesion and leucoplasia in epithelial and lichenoid inflammatory infiltrate

O líquen plano oral é uma doença potencialmente maligna e compartilha muitas características clínicas e histopatológicas com outras lesões semelhantes. O ALDH1 é um biomarcador específico na identificação de células-tronco, porém seu papel nas células estromais do infiltrado inflamatório imune não foi explorado. O objetivo deste estudo foi investigar a imunoexpressão de ALDH1 em células epiteliais e estromais de Líquen Plano Oral e outras lesões liquenóides. O estudo foi aprovado pelo Comitê de Ética em Pesquisa da Universidade Federal de Minas Gerais (UFMG) sob o parecer no 5.410.374, CAAE: 52763021.0.0000.5149. Foi realizada uma busca no arquivo do laboratório de Patologia Oral e Bucomaxilofacial da UFMG em um período de 10 anos (2011 ­ 2021) de casos diagnosticados como Líquen Plano oral, Lesão Liquenoide, Leucoplasia e Processo Inflamatório Inespecífico (controle). Foram selecionados 633 casos e após a utilização dos critérios de inclusão e exclusão, a expressão imuno-histoquímica do ALDH1 foi investigada em 64 casos, 16 de cada diagnóstico. O ALDH1 foi avaliado tanto no epitélio quanto nas células estromais do infiltrado inflamatório liquenóide. Um percentual de 5% de células ALDH1+ foi considerado positivo no epitélio. A avaliação das células estromais foi feita de forma semiquantitativa. Os campos foram classificados em escores, segundo os critérios: 1 (0 a 10%); 2 (11 a 50%) e 3 (mais de 51%). O valor médio da soma dos campos foi o escore final. Diferenças estatísticas entre os grupos foram investigadas e a significância foi estabelecida considerando p < 0,05. A análise estatística foi realizada utilizando o software: SPSS ­ Statistical Package for the Social Science® (versão 26.0, 2019, Chicago, IL, USA). A expressão de ALDH1 no epitélio foi baixa em todos os grupos sem diferença entre eles, embora a maioria dos casos tenha sido encontrada na amostra de inflamação crônica inespecífica. O escore de células ALDH1+ na lâmina própria foi maior para LPO (2,0), seguido por Leucoplasia (1,3), LLO (1,2) e processo inflamatório inespecífico (1,1) (p<0,05). A imunoexpressão do ALDH1 no epitélio de lesões com um infiltrado liquenóide não mostrou uma ferramenta contributiva, porém o ALDH1 em células estromais no infiltrado inflamatório do líquen plano merece atenção, pois pode estar envolvido no complexo processo de regulação imune associado à patogênese desta doença.

Oral lichen planus (OLP) is a potentially malignant lesion and shares clinical and histopathological features with similar lesions. ALDH1 is a specific biomarker in the identification of stem cells, but its role in the stromal cells of the immune inflammatory infiltrate has not been elucidated yet. The aim of this study was to investigate the ALDH1 immunoexpression in epithelial and stromal cells from OLP and other lichenoid lesions. The study was approved by the Research Ethics Committee of the Universidade Federal de Minas Gerais (UFMG) under protocol no 5.410.374, CAAE: 52763021.0.0000.5149. An search of the biopsy records of the Oral and Maxillofacial Pathology Laboratory at UFMG in a period of 10 years (2011 - 2021) was performed including the diagnosis of Oral Lichen Planus (OLP), Oral Lichenoid Lesion (OLL), Oral Leukoplakia (OLK) and Unspecific Inflammatory Process (UIP) ­ as control. Initially were obtained 633 cases. After inclusion and exclusion criteria a total of 64 cases were investigated for the ALDH1 immunohistochemical expression, 16 cases of each diagnose. ALDH1 was evaluated both in the epithelium and in the stromal cells. A percentage of ≤5% of ALDH1+ cells was considered positive in the epithelium. The evaluation of stromal cells was performed semi-quantitatively. The fields were classified into scores, according to the following criteria: 1 (0 to 10%); 2 (11 to 50%) and 3 (more than 51%). The mean value of the sum of the fields represented the final score. Statistical differences between groups were investigated and significance was established considering p < 0.05. Statistical analysis was performed using the software: SPSS ­ Statistical Package for the Social Science® (version 26.0, 2019, Chicago, IL, USA). The expression of ALDH1 in the epithelium was low in all groups with no difference between them, although most cases were found in the UIP samples. ALDH1+ cells in the lamina propria was higher for OLP (2.0) than others followed by OLK (1.3), OLL (1.2) and UIP (1.1) (p<0.05). The ALDH1 immunoexpression in the epithelium of lichenoid diseases did not prove to be contributory to show a malignant potential, but ALDH1 in stromal cells from OLP infiltrate might be involved in the complex immune regulation process associated with the pathogenesis of this disease.

Cancer Pro-oxidant Therapy Through Copper Redox Cycling: Repurposing Disulfiram and Tetrathiomolybdate.

BACKGROUND: Copper (Cu) is a transition metal active in Fenton redox cycling from reduced Cu+ and H2O2, to oxidized Cu2+ and the hydroxyl radical (·OH) highly reactive oxygen species (ROS). At homeostatic Cu levels, ROS promote cell proliferation, migration, angiogenesis, and wound repair. To limit ROS toxicity, cells use Cu-dependent chaperone proteins, Cu-binding ceruloplasmin, and Cu-modulated enzymes like superoxide dismutases (SOD) like SOD1 and SOD3 to scavenge excess superoxide anions which favour Cu+ reduction, and mitochondrial cytochrome c oxidase, important in aerobic energy production. Because Cu helps drive tumor cell proliferation by promoting growth factor-independent receptor tyrosine kinase signaling, and Cu-dependent MEK1 involved in oncogenic BRAF-V600E signaling, further augmenting bioavailable Cu may promote ROS overproduction, cancer progression and eventually tumor cell death. For these reasons, the following clinically approved copper chelators are being repurposed as anti-cancer agents: a) ammonium tetrathiomolybdate (TTM) used to treat Wilson's disease (copper overload) and Menkes disease (copper deficiency); b) Disulfiram (DSF), used against alcoholism, since it inhibits Aldehyde Dehydrogenase (ALDH1) enzyme, important in ethanol detoxification, and a key target against cancer stem cells. Moreover, TTM and DSF are also relevant in cancer clinical trials, because they increase the uptake of both Cu and Platinum (Pt)-containing anti-cancer drugs, since Pt and Cu share the same CTR1 copper transporter. PURPOSE: The majority of reports on Cu chelators dealt separately with either TTM, DSF or others. Here, we compare in parallel, the anti-cancer efficacy of low doses of TTM and DSF, asking whether they can be synergistic or antagonistic. The relevance of their unequal ROS inducing abilities and their different behavior as ionophores is also addressed. SIGNIFICANCE: The potential of Cu chelators as repurposed anti-cancer drugs, should be greater in patients with higher endogenous Cu levels. Since platinum and Cu share uptake receptors, the synergism by drugs containing these metals should not be under-estimated. The potential of disulfiram or its metabolically active Cu-containing form, to inhibit ALDH1-positive tumor cells is therapeutically very important.

rs3764435 Associated With Parkinson's Disease in Mexican Mestizos: Case-Control Study Reveals Protective Effects Against Disease Development and Cognitive Impairment.

Parkinson's disease (PD) is the second most common movement disorder. Genetic risk factors provide information about the pathophysiology of PD that could potentially be used as biomarkers. The ALDH1A1 gene encodes for the aldehyde dehydrogenase enzyme, which is involved in the disposal of toxic metabolites of dopamine. Due to the cytotoxic nature of aldehydes, their detoxification is essential for cellular homeostasis. It has been reported that ALDH1A1 expression levels and activity are decreased in PD patients. A deficit in ALDH1A1 activity in the substantia nigra, may lead to the accumulation of neurotoxic aldehydes and eventually the cell death seen in PD. One of the single nucleotide polymorphisms (SNP) that may modulate ALDH1A1 activity levels is rs3764435 (A/C). To investigate whether a statistical association exists between PD and the SNP rs3764435, we carried out a population-based Case-Control association study (120 PD patients and 178 non-PD subjects) in Mexican mestizos. DNA was extracted from blood samples and genotyped for rs3764435 using real-time PCR. A significant difference was found between PD cases and controls in both allelic and genotypic frequencies. The calculated OR showed that the C/C genotype is a protective factor under the codominant and recessive models of inheritance. However, after stratifying by sex, the protective role of this genotype is conserved only in men. Also, under the codominant and dominant models, rs3764435 appears to exert a protective effect against cognitive impairment in PD patients. Here for the first time, we show an association between PD and rs3764435 in a Mexican mestizo population, suggesting it confers neuroprotection for dementia in PD and is neuroprotective against developing PD in the males of this population. While analysis of the SNP looks favorable, replication of our study in cell lines or rs3764435 KO mice is required to validate these results.

CD44 and ALDH1 immunoexpression as prognostic indicators of invasion and metastasis in oral squamous cell carcinoma.

BACKGROUND: Tumour metastasis has been associated with cancer stem cells, a small population with stem-like cells properties, higher rate of migration and metastatic potential compared to cells from the tumour bulk. Our aim was to evaluate the immunoexpression of the putative cancer stem cell biomarkers ALDH1 and CD44 in primary tumour and corresponding metastatic lymph nodes. METHODS: Tumour tissue specimens (n = 50) and corresponding metastatic lymph nodes (n = 25) were surgically obtained from 50 patients with oral squamous cell carcinoma and submitted to immunohistochemistry. CD44 and ALDH1 were semi-quantitatively scored according to the proportion and intensity of positive cells within the invasive front and metastatic lymph nodes as a whole. A combined score was obtained by multiplying both parameters and later dichotomized into a final score classified as low (≤2) or high (>2) immunoexpression. RESULTS: ALDH1 immunoexpression and CD44 immunoexpression were detected in both tumour sites, although the means of ALDH1 (P = .0985) and CD44 (P = .4220) cells were higher in metastasis compared to primary tumours. ALDH1high was positively associated (P = .0184) with angiolymphatic invasion, while CD44high was positively associated (P = .0181) with metastasis (N+). At multivariate analysis, CD44 significantly increased the odds of lymph node metastasis, regardless of T stage (OR = 8.24; 1.64-65.64, P = .0088). CONCLUSIONS: CD44 immunoexpression was a significant predictor of lymph node metastasis, while ALDH1high immunostaining was associated with angiolymphatic invasion. Altogether, it suggests that immunoexpression of CD44 and ALDH1 links the cancer stem cell phenotype with oral squamous cell carcinoma invasion and metastasis.

Novel compound heterozygous mutations of ALDH1A3 contribute to anophthalmia in a non-consanguineous Chinese family

Abstract Anophthalmia is a rare eye development anomaly resulting in absent ocular globes or tissue in the orbit since birth. Here, we investigated a newborn with bilateral anophthalmia in a Chinese family. Exome sequencing revealed that compound heterozygous mutations c.287G > A (p.(Arg96His)) and c.709G > A (p.(Gly237Arg)) of the ALDH1A3 gene were present in the affected newborn. Both mutations were absent in all of the searched databases, including 10,000 in-house Chinese exome sequences, and these mutations were confirmed as having been transmitted from the parents. Comparative amino acid sequence analysis across distantly related species revealed that the residues at positions 96 and 234 were evolutionarily highly conserved. In silico analysis predicted these changes to be damaging, and in vitro expression analysis revealed that the mutated alleles were associated with decreased protein production and impaired tetrameric protein formation. This study firstly reported that compound heterozygous mutations of the ALDH1A3 gene can result in anophthalmia in humans, thus highlighting those heterozygous mutations in ALDH1A3 should be considered for molecular screening in anophthalmia, particularly in cases from families without consanguineous relationships.

ALDH1 and CD44 immunoexpression as prognostic indicators of invasion and metastasis in oral squamous cell carcinoma / Immunoexpressão de ALDH1 e CD44 como indicador de prognóstico de invasão e metástase em carcinoma epidermoide de boca

Oral squamous cell carcinoma (OSCC) is one of the most common cancer in the head and neck and results in high morbidity and mortality annually, being the worst prognosis related to the presence of metastasis in cervical lymph nodes. Metastasis has been associated with a subpopulation of tumor cells, called cancer stem cells (CSCs), which consists of a small population with stem-like cells properties, higher rate of migration and metastatic potential compared to other ordinary tumor cells from the tumor bulk. The aim of present study was to evaluate the immunoexpression of the CSC markers ALDH1 and CD44 in primary sites of OSCC and corresponding metastatic lymph nodes, by means of immunohistochemistry. The immunolabeling was further correlated with clinicopathological data. Archived Formalin-fixed, Paraffin-embedded tumor tissue specimens (n=50) and corresponding metastatic lymph nodes (n=25) were obtained from 50 patients with OSCC after surgical treatment. CD44 and ALDH1 immunostaining were semi-quantitatively scored according to the proportion and intensity of positive cells within the invasive front and metastatic cervical lymph nodes as a whole. The percentage of ALDH1 and CD44 positive tumor cells as well as immunostaining intensity was graded and a combined score, ranging from 0 to 9 (ALDH1) or 0 to 12 (CD44), was obtained by multiplying both parameters. Next, combined scores were dichotomized into a final score classified as low (ALDH1≤ 2; CD44≤ 4) or high (ALDH1> 2; CD44> 4) immunoexpression. ALDH1 and CD44 immunoexpression was detected in both primary and metastatic tumor sites, although with different immunolabeling pattern. ALDH1-positive tumor cells consisted of scattered patches and no immunoexpression was observed within keratin pearls. Conversely, CD44 immunopositivity was more homogeneous and widely distributed, with higher labeling in peripheral areas of the tumor islands within the tumor invasion front. Although not statistically significant, the means of ALDH1high (p= 0.0985) and CD44high (p= 0.1632; Mann- Whitney post-test) immunoexpression were higher in metastatic lymph nodes compared to primary tumors. ALDH1high was positively associated (p= 0.0184) with perivascular invasion, while CD44high was positively associated (p= 0.0186; Fisher's Exact Test) with metastasis (N+). Five-year survival rates tended to be lower in patients with ALDH1high immunoexpression compared to ALDH1low, although with no statistical significance (p= 0.1303). In summary, the present study revealed that CD44 is highly labeled in tumor cell from metastatic sites, being associated with lymph node metastasis, while ALDH1 high immunostaining was associated with perivascular invasion. Altogether, it suggests that immunoexpression of CD44 and ALDH1 links the cancer stem cell phenotype with OSCC invasion and metastasis.(AU)

O carcinoma epidermóide de boca (CEB) é uma das neoplasias mais comuns da região de cabeça e pescoço e resulta em alta morbidade e mortalidade anualmente, estando o pior prognóstico relacionado à presença de metástase em linfonodos cervicais. O processo de metástase tem sido associado a uma subpopulação de células tumorais, chamadas células-tronco de câncer (CSC, do inglês Cancer stem cells), que consistem em uma pequena população de células com propriedades de células-tronco, incluindo maior taxa de migração e potencial metastático em comparação com outras células tumorais. O objetivo do presente estudo foi avaliar os marcadores candidatos de CSCs ALDH1 e CD44 em tumores primários de CEB e metástases linfonodais correspondentes, por meio de imuno-histoquímica. A imunomarcação foi posteriormente correlacionada com dados clínico-patológicos. Foram obtidas amostras de tecido tumoral parafinado fixado em formalina (n = 50) e os linfonodos metastáticos correspondentes (n = 25) de 50 pacientes com CEB submetidos somente ao tratamento cirúrgico. Os marcadores CD44 e ALDH1 foram analisados de forma semi-quantitativa de acordo com a proporção e intensidade de células positivas no fronte de invasão e em linfonodos cervicais metastáticos como um todo. A porcentagem de células tumorais ALDH1 e CD44 positivas, bem como a intensidade da imunomarcação, foi classificada em um escore combinado obtido pela multiplicação de ambos os parâmetros, variando de 0 a 9 (ALDH1) ou 0 a 12 (CD44). Em seguida, as pontuações combinadas foram dicotomizadas em um escore final classificado como baixo (do inglês low) (ALDH1 ≤ 2; CD44 ≤ 4) ou alto (do inglês high) (ALDH1> 2; CD44> 4). A imunoexpressão de ALDH1 e CD44 foi detectada tanto em tumores primários quanto em linfonodos cervicais metastáticos, embora com padrão diferente de imunomarcação. Células tumorais ALDH1-positivas foram identificadas como focais e dispersas ao longo do fronte de invasão, sem imunomarcação nas pérolas córneas. Em contraste, a imunopositividade para CD44 foi mais homogênea e amplamente distribuída, com maior imunomarcação em áreas periféricas das ilhotas tumorais presentes no fronte de invasão. Embora não estatisticamente significativa, as médias da imunoexpressão ALDH1high (p = 0.0985) e CD44high (p = 0.1632, pós-teste de Mann-Whitney) foram maiores em linfonodos metastáticos em comparação com tumores primários. ALDH1high foi positivamente associado com invasão perivascular (p = 0.0184), enquanto CD44high foi com metástase (N+) (p = 0.0186; teste exato de Fisher). As taxas de sobrevida global em 5 anos tenderam a ser mais baixas em pacientes com imunoexpressão elevada de ALDH1 em comparação com ALDH1low, embora sem significância estatística (p = 0.1303). Em resumo, o presente estudo revelou que a elevada imunomarcação de CD44 está significativamente associada com metástases linfonodais, enquanto que a elevada imunomarcação de ALDH1 está associada com invasão perivascular. Em conjunto, sugerimos que a imunoexpressão de CD44 e ALDH1 esteja relacionada com o fenótipo de células tronco de câncer que tem capacidade de invasão e metástase em CEB.(AU)

Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.

BACKGROUND: The metabolic inhibitor 3-bromopyruvate (3-BrPA) is a promising anti-cancer alkylating agent, shown to inhibit growth of some colorectal carcinoma with KRAS mutation. Recently, we demonstrated increased resistance to 3-BrPA in wt p53 tumor cells compared to those with p53 silencing or mutation. Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation. Since hypoxia increases the toxicity of the p53 activator, Prima-1 against breast cancer cells irrespective of their p53 status, we also investigated whether Prima-1 reversed hypoxic resistance to 3-BrPA. RESULTS: In contrast to the high susceptibility of hypoxic mutant NRAS MelJuso cells to 3-BrPA or Prima-1, KRAS mutant C8161 and A549 cells revealed hypoxic resistance to 3-BrPA counteracted by Prima-1. In A549 cells, Prima-1 increased p21CDKN1mRNA, and reciprocally inhibited mRNA expression of the SLC2A1-GLUT1 glucose transporter-1 and ALDH1A1, gene linked to detoxification and stem cell properties. 3-BrPA lowered CAIX and VEGF mRNA expression. Death from joint Prima-1 and 3-BrPA treatment in KRAS mutant A549 and C8161 cells seemed mediated by potentiating oxidative stress, since it was antagonized by the anti-oxidant and glutathione precursor N-acetylcysteine. CONCLUSIONS: This report is the first to show that Prima-1 kills hypoxic wt p53 KRAS-mutant cells resistant to 3-BrPA, partly by decreasing GLUT-1 expression and exacerbating pro-oxidant stress.

Isolation and culture of stem cells derived from dental pulp of permanent teeth: a successful method / Isolation and culture of stem cells derived from dental pulp of permanent teeth: a successful method

Objective: To establish cultures of cells from the pulp of permanent teeth by the explant method assessing parameters usually presented by stem cells, such as the expression of certain markers and the differentiation ability into osteogenic, adipogenic, and chondrogenic lineages. This study also aimed to assess the expression of ALDH1 (aldehyde dehydrogenase 1) enzyme activity on the isolated cells. Materials and method: The pulp tissue, obtained from wisdom teeth, was placed in a 6-well plate containing proper culture medium, and stored at 37 °C and 5% CO2 for cell proliferation and plastic adherence. Cells were tested for the expression of surface markers and for ALDH1 enzyme activity, by flow cytometry. In addition, cells were assessedfor multi-differentiation potential. Results: The isolated cells showed high expression of CD44 (98.8%), CD73 (100%), and CD90 (97.2%), and moderate expression of STRO-1 (18.4%) and ALDH1 (16.2%), by flow cytometry. Similarly, the cells showed differentiation ability into all three lineages of cells tested. Conclusion: Our results suggest that the explant method - or cell proliferation method - is suitable for the isolation and cultureof stem cells from dental pulp of permanent teeth. The isolated cells may be considered stem cells, based on the current criteria for their characterization, such as plastic adherence, expression of certain markers, and the absence of others, as well as multi-differentiation potential, which showed to be promising for the application in tissue regeneration.

Liver cancer stem cells are selectively enriched by low-dose cisplatin

Accumulating evidence has indicated the importance of cancer stem cells in carcinogenesis. The goal of the present study was to determine the effect of low-dose cisplatin on enriched liver cancer stem cells (LCSCs). Human hepatoblastoma HepG2 cells were treated with concentrations of cisplatin ranging from 1 to 5 μg/mL. Cell survival and proliferation were evaluated using a tetrazolium dye (MTT) assay. LCSCs were identified using specific markers, namely aldehyde dehydrogenase-1 (ALDH1) and CD133. The percentage of ALDH1+ or CD133+ cells was examined by flow cytometric analysis. The expression of ALDH1 and/or CD133 in HepG2 cells was determined by immunocytochemical analysis. Low-dose cisplatin treatment significantly decreased cell survival in HepG2 cells after 24 or 72 h. However, the percentage of LCSCs in the surviving cells was greatly increased. The percentage of ALDH1+ or CD133+ cells was increased in a time- and dose-dependent manner after treatment with 1-4 μg/mL cisplatin, whereas 5 μg/mL cisplatin exposure slightly reduced the number of positive cells. These findings indicate that low-dose cisplatin treatment may efficiently enrich the LCSC population in HepG2 cells.

Avaliação da imunomarcação de células-tronco tumorais em carcinossarcomas mamários e carcinomas em tumores mistos em cadelas / Evaluation of immunostaining of tumor stem cells in mammary carcinosarcomas and carcinomas in mixed tumors in bitches

As células-tronco tumorais (CTTs) pertencem a uma pequena população de células dentro do tumor com propriedades de autorrenovação e diferenciação em outros tipos celulares. Neste estudo avaliou-se o comportamento tanto das porções mesenquimais quanto das epiteliais de seis carcinossarcomas (CSs), 11 carcinomas em tumores mistos (CTMs) grau I, 11 grau II e 10 grau III. Nas porções epiteliais dos CS e CTM foram observadas imunomarcações para os anticorpos CD44, CD24, Oct-4 e ALDH-1. Nas porções mesenquimais dos CS, nas porções epiteliais dos CTMs graus II e III não houve imunomarcação para o ALDH-1. Concluiu-se que as CTTs são expressas em proporções iguais tanto nas porções mesenquimais quanto nas epiteliais dos CSs e ausentes nas porções mesenquimais bem diferenciadas de CTMs.(AU)

Cancer stem cells belong to a small population of cells within the tumor with properties of self-renewal and differentiation into other cell types. In this study, the behavior of both portions, mesenchymal and epithelial, was evaluated. Six carcinosarcomas (CSs), 11 carcinomas within mixed tumors (CWMTs) grade I, 11 grade II, and 10 grade III were evaluated. In the epithelial portions of the CS and CWMTs was observed immunostaining for antibodies CD44, CD24, Oct-4 and ALDH-1. In the mesenchymal portions of the CS, in the epithelial portions of CMTs grades II and III no immunostaining for ALDH-1 was found. It was concluded that the tumor stem cells are expressed in equal proportions in the epithelial and mesenchymal portions of the CS. No immunostaining in the mesenchymal portions of well-differentiated CWMTs was seen.(AU)

Avaliação da imunomarcação de células-tronco tumorais em carcinossarcomas mamários e carcinomas em tumores mistos em cadelas / Evaluation of immunostaining of tumor stem cells in mammary carcinosarcomas and carcinomas in mixed tumors in bitches

As células-tronco tumorais (CTTs) pertencem a uma pequena população de células dentro do tumor com propriedades de autorrenovação e diferenciação em outros tipos celulares. Neste estudo avaliou-se o comportamento tanto das porções mesenquimais quanto das epiteliais de seis carcinossarcomas (CSs), 11 carcinomas em tumores mistos (CTMs) grau I, 11 grau II e 10 grau III. Nas porções epiteliais dos CS e CTM foram observadas imunomarcações para os anticorpos CD44, CD24, Oct-4 e ALDH-1. Nas porções mesenquimais dos CS, nas porções epiteliais dos CTMs graus II e III não houve imunomarcação para o ALDH-1. Concluiu-se que as CTTs são expressas em proporções iguais tanto nas porções mesenquimais quanto nas epiteliais dos CSs e ausentes nas porções mesenquimais bem diferenciadas de CTMs.

Cancer stem cells belong to a small population of cells within the tumor with properties of self-renewal and differentiation into other cell types. In this study, the behavior of both portions, mesenchymal and epithelial, was evaluated. Six carcinosarcomas (CSs), 11 carcinomas within mixed tumors (CWMTs) grade I, 11 grade II, and 10 grade III were evaluated. In the epithelial portions of the CS and CWMTs was observed immunostaining for antibodies CD44, CD24, Oct-4 and ALDH-1. In the mesenchymal portions of the CS, in the epithelial portions of CMTs grades II and III no immunostaining for ALDH-1 was found. It was concluded that the tumor stem cells are expressed in equal proportions in the epithelial and mesenchymal portions of the CS. No immunostaining in the mesenchymal portions of well-differentiated CWMTs was seen.

Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.

Polycomb Repressive Complex 2 (PRC2) mediates transcriptional silencing by catalyzing histone H3 lysine 27 trimethylation (H3K27me3), but its role in the maturation of postmitotic mammalian neurons remains largely unknown. We report that the PRC2 paralogs Ezh1 and Ezh2 are differentially expressed during hippocampal development. We show that depletion of Ezh2 leads to increased expression of PSD-95, a critical plasticity gene, and that reduced PSD-95 gene transcription is correlated with enrichment of Ezh2 at the PSD-95 gene promoter; however, the H3K27me3 epigenetic mark is not present at the PSD-95 gene promoter, likely due to the antagonizing effects of the H3S28P and H3K27Ac marks and the activity of the H3K27 demethylases JMJD3 and UTX. In contrast, increased PSD-95 gene transcription is accompanied by the presence of Ezh1 and elongation-engaged RNA Polymerase II complexes at the PSD-95 gene promoter, while knock-down of Ezh1 reduces PSD-95 transcription. These results indicate that Ezh1 and Ezh2 have antagonistic roles in regulating PSD-95 transcription.